Who
Clive Meanwell
Director
Company insider
Files Form 4 as: Director, Fractyl Health; Executive Chairman, Metsera; Director, EQRx; Director and 10% owner, Invivyd; Chief Executive Officer, Population Health Investment Co; Chief Innovation Officer, Medicines Co /de; Director, Endo Pharmaceuticals Holdings.
In numbers
- Trades disclosed
- 265
- Buys
- 2
- Sells
- 65
- Bought
- $220K
- Sold
- $37.5M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 14 Feb 2006
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code A | —5,375 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —32,250 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —297,907 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metsera | SEC FORM 4 Code D | —5,375 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metsera | SEC FORM 4 Code D | —12,767,462 | filing |
| 11 Jun 2025filed 13 Jun 2025 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | Metseraoption or derivative | SEC FORM 4 Code A | —32,250 at $0.00 | filing |
| 6 Feb 2024filed 8 Feb 2024 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code C | —596,352 | filing |
| 6 Feb 2024filed 8 Feb 2024 | GUTS Fractyl HealthMedical Devices | SEC FORM 4 Code C | —277,890 | filing |
| 1 Feb 2024filed 5 Feb 2024 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 9 Nov 2023filed 9 Nov 2023 | EQRxoption or derivative | SEC FORM 4 Code D | —313,500 at $0.00 | filing |
| 9 Nov 2023filed 9 Nov 2023 | EQRxoption or derivative | SEC FORM 4 Code D | —101,010 at $0.00 | filing |
| 9 Nov 2023filed 9 Nov 2023 | EQRxoption or derivative | SEC FORM 4 Code D | —43,172 | filing |
| 23 May 2023filed 25 May 2023 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jan 2023filed 4 Jan 2023 | EQRxoption or derivative | SEC FORM 4 Code A | —226 | filing |
| 30 Sep 2022filed 4 Oct 2022 | EQRxoption or derivative | SEC FORM 4 Code A | —101,010 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 17 Dec 2021filed 20 Dec 2021 | EQRxoption or derivative | SEC FORM 4 Code A | —313,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.